At 71, She Chose Local NSCLC Treatment Over a Boston Trial

The notebook was already open when her specialist entered the exam room.

She had started it in November 2020, when imaging found non-small cell lung cancer in one lung and surgery removed the affected lobe. A retired high school English teacher, she recorded what she feared she might forget: appointment months, medication changes, questions for the next visit and the distances between scans. Her wife kept the notebook in a kitchen drawer after the follow-up visits grew less frequent.

For nearly four years, the entries became brief. Scan stable. Next appointment in six months. A blood test to repeat.

The ordinary language mattered because it allowed them to return home, make dinner and talk about something else.

Then, in November 2024, a portal notice appeared before the scheduled appointment. The report described a new area of concern near the site of the earlier cancer and another finding that needed review. She read the paragraph twice, shut the laptop and took the notebook from the drawer.

At the hospital, her specialist explained that further testing supported a recurrence of NSCLC. It was not the news she had expected after four years, though she understood recurrence had always been possible. She felt fear first. Anger arrived later, directed nowhere useful.

Her wife wrote recurrence beneath the date, pressing hard enough to leave marks on the next page.

Two treatment paths

The local cancer team presented a standard treatment plan that could be given at a regional center 52 minutes from their home. The drugs and likely side effects were familiar to the clinicians, who could describe what had been observed in other patients while remaining clear that no estimate could predict her individual result.

A second possibility came through a specialist in Boston: a clinical trial testing an investigational drug alongside established treatment. The trial might offer access to a treatment not otherwise available, but there was no promise that it would work better, and its added benefit was the point still being studied.

She drew a line down a fresh notebook page. Standard went on one side. Trial went on the other.

The local plan involved treatment every few weeks, with additional visits for bloodwork and follow-up. The Boston trial required screening, repeat imaging and frequent appointments during the first ten weeks, some close enough together that driving home between them made little sense. Later visits could become less frequent, provided her health and the study schedule allowed it.

The differences did not fit neatly into the two columns. The standard option had more evidence behind it, but that did not mean certainty. The trial offered possibility, but also procedures and travel that would exist even if the investigational drug did not help her.

She had spent her career telling students to support a conclusion with evidence. Now the available evidence could describe groups of people, common effects and unanswered questions, while the decision belonged to one body and one household.

The notebook became a map of the decision, though some of its most important territory could not be measured.

What the road would require

Their home was roughly three hours from Boston in light traffic. The same drive could take much longer after snow, during road work or near the city, and neither woman liked driving there after dark. Her wife, 69, was willing to do it. Willing was not the same as unworried.

At the kitchen table, they calculated eight early trial visits based on the schedule they had been given. A day trip would cost about $84 for gas, parking and food. An overnight stay pushed their estimate to $236, before any unexpected expense. Their insurance covered routine medical care that met the plan’s rules, while the study sponsor covered research-related care, but meals and most travel costs would remain theirs unless a support fund approved assistance.

The total they wrote down for the first ten weeks was $1,712. It was not beyond their savings. That almost made the decision harder, because they could not dismiss the trial as impossible.

Money was only one cost. Each Boston visit would take most of a day, and bad weather could turn it into an overnight trip. They would need to arrange care for their dog. Her wife would carry the driving while also listening during appointments, taking notes and trying not to reveal how tired she felt.

Her wife initially leaned toward the trial. She wanted every reasonable option considered, and the investigational treatment seemed to represent an additional chance. The retired teacher heard that hope without sharing all of it. She did not want the next season organized around the highway, yet she worried that declining the study would look, later, like a failure of courage.

They argued once about the word burden. Her wife thought it made the travel sound more important than the cancer. She meant that the travel was part of living with the cancer, and therefore belonged in the decision.

Both were frightened. Neither was confused about loving the other.

Asking what the evidence could answer

A remote conversation with the trial team helped separate what was known from what they had begun to imagine. The investigational drug had reached the stage where researchers were studying its effect in a larger group, but questions remained about benefit and side effects. Participation could end if the cancer progressed, if adverse effects became unacceptable or if she chose to withdraw.

The team also explained that trial care would follow a fixed protocol. Some tests could be done closer to home, but many study assessments had to happen in Boston. Scheduling changes were possible in limited circumstances, not as a general answer to winter roads.

She wrote four phrases in the notebook: possible benefit, added unknowns, fixed visits and can leave. They were her words, not a transcript of what anyone had said.

The local specialist did not frame standard treatment as surrendering an opportunity. It was an established option supported by evidence, with uncertainty of its own. The specialist also acknowledged that choosing the trial would be reasonable if its research question and practical demands matched what mattered to her.

That absence of pressure gave her relief. She had expected a correct answer to emerge if she gathered enough information. Instead, the information defined the trade-offs more sharply.

Quality of life came up often, but the phrase felt too broad until she and her wife described an ordinary week. They wanted breakfast at home. They wanted walks when the roads were clear and visits from family that were not repeatedly moved around trips to Boston. She wanted enough energy to read and to keep helping a former colleague with the school literary magazine, though she knew treatment might narrow those plans whichever option she chose.

There was no guarantee that staying near home would preserve those routines. Standard treatment could bring difficult side effects and unplanned hospital visits. The local center was still almost an hour away. Winter would still happen.

She circled the travel total anyway.

Choosing the known route

Three weeks after learning the cancer had returned, she chose standard treatment at the regional center. The decision followed a second review of her records and another discussion of the trial, during which no new fact settled the matter for her. She remained eligible to ask about other studies later, depending on her health and what options were available then.

Her wife needed longer to accept the choice. She worried they were leaving something unused. The retired teacher worried about that too, but she felt more certain that she did not want to spend the first months after recurrence traveling to Boston as often as the trial required.

They did not turn the choice into a statement about how everyone should respond to recurrent cancer. Another person might value early access to an investigational drug more than predictable time at home, live closer to the study site or have fewer concerns about the road. Their own decision came from the evidence available to them and from limits that were not failures.

At her first local treatment visit, the notebook sat in her wife’s lap. It now contained the original surgery notes, four years of scan results and the divided page comparing the trial with standard care. The $1,712 estimate remained circled.

They had not crossed out the trial column.

Questions people ask

Is recurrent NSCLC always treated the same way?

No. In this story, the clinicians reviewed where the cancer had returned, her prior treatment, test results and general health before discussing options. The available approaches and their goals can differ from one person to another, which is why her standard plan and trial eligibility were considered together rather than as interchangeable choices.

Does joining a clinical trial mean receiving better treatment?

A trial studies an unanswered question, so better results are not guaranteed. The Boston study offered access to an investigational drug alongside established treatment, but it also involved unknowns and required protocol visits. She considered that possibility meaningful without treating it as proof that the trial would help her more.

Can quality of life be part of a cancer treatment decision?

Quality of life was central to her discussions with both treatment teams. She and her wife considered side effects, time at home and the strain of winter travel alongside the medical evidence. Those priorities did not replace clinical information; they helped the couple understand what each option would ask of their shared life.

Who pays for travel connected to a clinical trial?

Coverage varied by the type of care and the study’s policies. Her insurance was expected to cover qualifying routine care, while the sponsor covered research-related costs, but most transportation, parking and meals remained uncertain. She wrote the uncovered estimates beside each Boston visit in the notebook.